AstraZeneca/MedImmune Oncology Portfolio
Opportunities for Local Sponsorship via Combinations Alliance
“Open EOI Call”
April 2015
Further to the request from the Combinations Alliance for clarity on which drugs and areas of scientific interest are open for
collaboration under the master terms of agreement, AstraZeneca/MedImmune are pleased to provide this detail as follows.
Any proposals that are of interest and that AZ/MedImmune and our Alliance partners would be keen to progress, will be
reviewed by AZ/MedImmune internal governance in order to secure appropriate funding prior to a decision
All proposals will be prioritised based on scientific merit and fit with the core development program of the drug. The areas outlined below for
each project are not at the exclusion of others with a strong scientific rationale, and all proposals will be considered on a case-by-case basis
for External Sponsored Research (ESR) via the Combinations Alliance.
AZD1775 (Wee1 inhibitor) Project representative: Robert.E.Godin@astrazeneca.com

Development stage - Phase II

Settings of interest - Please contact the project representative to discuss prioritized clinical settings for external collaboration.
Collaborators may need to generate additional preclinical work to support clinical settings of interest.
AZD2014 (mTOR inhibitor) Project representative: christopher.shepherd@astrazeneca.com

Development stage - Phase II

Settings of interest - As the strategy is currently undergoing review, please contact Christopher Shepherd in the first instance. Any
new proposals must be supported by strong pre-clinical or clinical data.
Selumetinib (MEK inhibitor) Project representative: desiree.headley@astrazeneca.com

Development stage - Phase III: 25mg capsules available

Settings of interest - Combinations with chemo/cytotoxic agents; Combinations with novel agents, including immunotherapy;
Studies to identify biomarkers of MAPK pathway activation that could support future clinical studies; Studies to enhance patient
selection approaches, leading to less invasive sampling or improved platforms for multiple testing
AZD9291 (EGFR sensitising and T790M Resistance Mutations Inhibitor) Project representative: paramjit.kaur@astrazeneca.com

Development stage - Pivotal P2 studies in EGFRm T790M positive NSCLC are completed; phase 3 study is ongoing; Ph3 in EGFRm
NSCLC, treatment naive is ongoing; phase 1 / 2 studies with AZD9291 + novel combinations are ongoing. Recommended phase II
dose of 80 mg once daily is confirmed for AZD9291

Settings of Interest: AZD9291 is a potent, selective, irreversible oral EGFR TKI inhibitor of both EGFRm (TKI-sensitivity conferring
mutations) and T790M (TKI-resistance conferring mutation) receptor forms of EGFR
o Combinations – novel agents, SOC
o Patient populations under-represented in clinical programme
o Diagnostics – sampling, techniques, platforms,
o Translational – resistance patterns
o Adverse Event Management and Characterisation
AZD9150 (STAT3rx antisense oligonucleotide) Project representative: esha.gangolli@astrazeneca.com

Development stage - Phase II

Settings of Interest – Immunotherapy combinations, in particular studies with a strong investigative biomarker component. Please
contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to
generate additional preclinical work to support clinical settings of interest.
AZD6738 (ATR inhibitor) Project representative: simon.a.smith@astrazeneca.com

Development stage - Phase I

Settings of interest - Monotherapy and combination studies in B-cell tumours only, such as CLL, mantle cell lymphoma and diffuse
large B cell lymphoma.
AZD8186 (PI3K/ selective inhibitor) Project representative: esha.gangolli@astrazeneca.com

Development stage - Phase I

Settings of interest - Combination studies in tumour types where PTEN deficiency is common or in settings that are PI3Kbeta
signalling dependent without PTEN-driven mechanisms and in particular, studies with a strong translational component . Please
contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to
generate additional preclinical work to support clinical settings of interest.
AZD8835 (PI3Ka/ selective inhibitor) Project representative: esha.gangolli@astrazeneca.com

Development stage - Phase I

Settings of interest - Combination studies, including with immunotherapy, in tumour types driven by PIK3CA activation. Please
contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to
generate additional preclinical work to support clinical settings of interest.
Medi3617 (anti-angiogenesis monoclonal antibody) Project representative: dominic.lai@medimmune.com

Development stage - Phase I/2

Settings of interest - Monotherapy and combination studies in glioblastoma multiforme.
1
WEBINAIR SCHEDULE
Date:
Time:
Topic:





Monday, 27 April 2015
14:00, GMT Summer Time (London, GMT+01:00)
Project Compounds
AZD1775 WEE 1 Kinase Inhibitor (Rob Godin)
Selumetinib MEK 1/2 Inhibitor (Desiree Headley)
AZD9291 EGFR TKI (Paramjit Kaur)
AZD2014 mTORC1/2 Inhibitor (Chris Shepherd)
Medi 3617 anti-ANG2 mAb (Dominic Lai)
Date:
Time:
Topic:




Tuesday, 5 May 2015
13:00, GMT Summer Time (London, GMT+01:00)
Project Compounds 2
AZD6738 ATR Inhibitor (Simon Smith)
AZD8186 PI3Kb/d inhibitor (Esha Gangolil)
AZD8835 PI3Ká/d inhibitor (Esha Gangolli)
AZD9150 STAT3rx antisense oligonucleotide (Esha Gangolli)
Meeting Number: 680 519 483
Meeting Password: oncology
Meeting Number: 680 521 491
Meeting Password: oncology
To join the meeting go to:
https://astrazeneca.webex.com/astrazeneca/j.php?MTID=mff636
4b20aeb9c08e2927f95d32dfefd
To join the meeting go to:
https://astrazeneca.webex.com/astrazeneca/j.php?MTID=mac938cb
2727f5a6b18d8c942ecabda5b
Audio Conference:
Conference code: 17861443
Global Access Numbers Local:
United Kingdom: +44(0) 208 118 1014
United States:
678.905.7177
Sweden:
0850 619 664
For Assistance:
Go to https://astrazeneca.webex.com/astrazeneca/mc
2. On the left navigation bar, click "Support".
To add this meeting to your calendar program (for example Microsoft Outlook), click this link:
https://astrazeneca.webex.com/astrazeneca/j.php?MTID=m6a033011bc0a29ee9e3a2a59d3ffe6e0
To check whether you have the appropriate players installed for UCF (Universal Communications Format) rich media files, go to
https://astrazeneca.webex.com/astrazeneca/systemdiagnosis.php.
http://www.webex.com
Recording:
The web-ex presentations on 27th April and 5th May will be recorded. Any Investigator who is unable to attend the web-ex sessions
can request access to the recordings. These will be password protected and a CDA will need to be in place to enable these recordings to
be shared. Please contact Graham Fisher (graham.fisher@astrazeneca.com) in the first instance.
2